Cytokines in Liver Injury and Repair

Preface. Section I: Cytokine-Induced Cell Death. 1. Endogenous modulators of receptor-mediated hepatic cell death; H. Hentze, et al. 2. Modulation of CD 95 (APO-1/Fas) induced hepatocyte death by NO; PR. Galle, et al. 3. TGF-beta-induced liver cell apoptosis; R. Schulte-Hermann, et al. Section II: Regulation of Normal and Malignant Cell Growth by Cytokines. 4. Proliferative and apoptotic effects of tumour necrosis factor in the liver and cells in culture; N. Fausto, J. Campbell. 5. The role of insulin-like growth factor-II in hepatocarcinogenesis; P. Lund, et al. 6. Transforming growth factor-beta and cancer; M. Reiss. 7. Cytokines and hepatitis C virus replication; D. Moradpour, et al. Section III: Cytokine Signals in Fibrogenesis. 8. Role of DDR2 receptor in the activation of hepatic stellate cells; E. Olaso, et al. 9. PDGF signalling in activated stellate cells; M. Pinzani. 10. Escape of activated hepatic stellate cells from TGF-beta control; S. Dooley, et al. 11. Chemokines in the modulation of liver inflammation; F. Marra, et al. Section IV: Modulation of Fibrogenic Cytokine Response. 12. Identification of fibrogenic genes in a polygenic mouse model of liver fibrosis; F. Lammert, et al. 13. Cytokine transgenic models of fibrogenesis; S. Kanzler. 14. The fibrogenic mediators of TGF-beta and TNF-alpha as surviving factors for activated hepatic stellate cells; G. Ramadori, B. Saile. 15. Resolution of fibrosis by apoptosis of myofibroblasts; F. Murphy, J.P. Iredale. Section V: Cytokines in the Cause and Consequence of Cholestatis. 16. Regulation of hepatic organic anion transporters by cytokines; A. Geier, et al. 17. Reaction of cholangiocytes to inflammatory injury; C. Spirli, et al. 18. Bid antisense oligodeoxynucleotides as therapy for cholestatic liver injury; H. Higuchi, G.J. Gores. Section VI: Polymorphisms of Cytokines and Signalling. 19. Regulation of interleukin-6-type cytokine signaling; P.C. Heinrich, et al. 20. IL6-dependent signal transduction and its relevance in animal models; K.L. Streetz, et al. 21. Predictive value of cytokine polymorphisms for liver disease; P.T. Donaldson, C.P. Day. Section VII: Therapeutic Cytokines and Modulators. 22. PPARgamma and fibrogenesis; T. Miyahara, et al. 23. Cytokine modulation in the therapy of hepatic immunopathology and fibrosis; S.M. Wahl, et al. 24. Matrix binding motifs and peptide mimetics as modulators of wound healing and fibrogenesis; D. Schuppan, et al. 25. Endothelin and liver injury -- therapeutic antagonism of the endothelin system; D.C. Rockey. 26. Transforming growth factor ss in the treatment of autoimmune disease; A.W. Lohse. Section VIII: Cytokine-Assisted Gene Therapies. 27. The feasibility of antifibrotic gene therapy; T.J. Davern, D.M. Bissell. 28. Experimental approaches to antifibrotic strategies using gene transfer; R. Weiskirchen, et al. 29. Cytokine-assisted gene therapy: Anti-TGF-ss intervention using mutated forms of TGF-ss receptor; H. Ueno, et al. 30. Cytokine-based gene therapy of hepatocellular carcinoma (HCC); C. Qian, et al. Index.